home / stock / rlyb / rlyb news

RLYB News and Press, Rallybio Corporation From 02/03/26

Stock Information
Company Name: Rallybio Corporation
Stock Symbol: RLYB
Market: NASDAQ
Website: rallybio.com
Menu
RLYB RLYB Quote RLYB Short RLYB News RLYB Articles RLYB Message Board
Get RLYB Alerts

News, Short Squeeze, Breakout and More Instantly...
RLYB - Rallybio to implement 1-for-8 reverse stock split

2026-02-03 16:23:42 ET More on Rallybio Seeking Alpha’s Quant Rating on Rallybio Historical earnings data for Rallybio Financial information for Rallybio Read the full article on Seeking Alpha For further details see: Rallybio to implement ...
RLYB - Rallybio GAAP EPS of $0.36 beats by $0.57, revenue of $0.2M beats by $0.13M

2025-11-06 12:34:58 ET More on Rallybio Seeking Alpha’s Quant Rating on Rallybio Historical earnings data for Rallybio Financial information for Rallybio Read the full article on Seeking Alpha For further details see: Rallybio GAAP EPS of $...

RLYB - Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates

– RLYB116 Confirmatory PK/PD Study Data Expected in 4Q 2025 – – Generated $20 Million from Sale of Interest in REV102 – – Cash Runway Extended through 2027 – Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology c...

RLYB - Expected US Company Earnings on Thursday, November 6th, 2025

Avidity Biosciences Inc. (RNA) is expected to report $-1.05 for Q3 2025 Universal Electronics Inc. (UEIC) is expected to report $-0.15 for Q3 2025 Intercorp Financial Services Inc. (IFS) is expected to report $1.15 for Q3 2025 Clear Secure Inc. Class A (YOU) is expected to report $0.2...
RLYB - Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

– Interim Data Support Advancing RLYB116 as a Differentiated Therapeutic and Enable Progression to Cohort 2 – – Data Readouts for Completed Study Expected in 4Q 2025 – Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company t...

RLYB - Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program

– Milestone Payment Triggered by Initiation of Additional Preclinical Studies for REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia – – Extends Cash Runway through 2027 – Rallybio Corporation (Nasdaq: RLYB), a clin...

RLYB - Avant Technologies and Ainnova Tech Announce Enhanced Patient Recruitment Strategy Ahead of FDA Clinical Trial

2025-08-12 09:27:16 ET Las Vegas, NV – August 12, 2025 – Avant Technologies Inc. (OTCQB: AVAI) (“Avant” or the “Company”), an emerging technology company developing healthcare solutions, and its Joint Venture partner, Ainnova Tech, Inc. (Ainnova...
RLYB - Expected earnings - Rallybio Corporation

Rallybio Corporation (RLYB) is expected to report for Q2 2025

RLYB - Rallybio GAAP EPS of -$0.22, revenue of $212K

2025-08-07 09:42:17 ET More on Rallybio Recursion to buy Rallybio’s ownership in jointly developed bone disorder drug Seeking Alpha’s Quant Rating on Rallybio Historical earnings data for Rallybio Financial information for Rallybio Rea...

RLYB - Rallybio GAAP EPS of -$0.22, revenue of $212M

2025-08-07 09:42:17 ET More on Rallybio Recursion to buy Rallybio’s ownership in jointly developed bone disorder drug Seeking Alpha’s Quant Rating on Rallybio Historical earnings data for Rallybio Financial information for Rallybio Rea...
Previous 10 Next 10